Sotigalimab
- Generic Name
- Sotigalimab
- Drug Type
- Biotech
- CAS Number
- 2305607-45-6
- Unique Ingredient Identifier
- JEA93WJ5DG
- Background
Sotigalimab is under investigation in clinical trial NCT03123783 (CD40 Agonistic Antibody APX005M in Combination With Nivolumab).
Pipeline Progress: Over 25 New Therapies in Development for Metastatic Liver Cancer
• DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options.
• Several promising clinical trials are underway in 2025, including studies evaluating novel combinations such as AK104 plus lenvatinib, tislelizumab with lenvatinib, and triplet therapy of nivolumab, relatlimab and bevacizumab.
• Key emerging therapies include exoASO-STAT6 targeting tumor-associated macrophages, STP705 dual TGF-ß1/COX-2 inhibitor, and ONCR-177, an oncolytic viral immunotherapy expressing five transgenes to fight tumors through multiple mechanisms.
Gastrointestinal Cancer Symposium 2025: Key Advances in Treatment Strategies
• Nivolumab plus ipilimumab demonstrates superior progression-free survival compared to nivolumab alone in MSI-H/dMMR metastatic colorectal cancer.
• Encorafenib combined with cetuximab and chemotherapy shows significant improvement in overall response rate for BRAF V600E-mutated metastatic colorectal cancer.
• TACE plus camrelizumab and rivoceranib extends progression-free survival in patients with unresectable hepatocellular carcinoma, offering a manageable safety profile.
Esophageal Cancer Treatment Landscape Evolves with Novel Therapies and Approvals
• The esophageal cancer market is expected to grow significantly, driven by increasing prevalence and the introduction of novel therapies.
• In 2023, approximately 77,000 new cases of esophageal cancer were reported across seven major markets, with Japan having the highest number.
• Recent FDA approval of TEVIMBRA (tislelizumab) as a monotherapy marks a significant advancement in treating unresectable or metastatic ESCC.
• Emerging therapies like zanidatamab and bemarituzumab are expected to revolutionize the esophageal cancer market dynamics during the forecast period.
Sotigalimab Plus Chemoradiotherapy Shows Promise in Rectal Cancer
• The phase 2 INNATE trial evaluated sotigalimab in combination with chemoradiotherapy for rectal cancer, showing a safe and feasible profile.
• Patients receiving sotigalimab had a pathological complete response (pCR) rate of 22.2% compared to 14.3% in the control arm.
• Grade 3/4 adverse events were lower in the sotigalimab arm (26%) compared to the control arm (45%).
• The trial demonstrated a clear pharmacodynamic impact and evidence of adaptive immunity with sotigalimab addition.
Combination Immunotherapies Show Promise in Pancreatic Cancer Treatment
• Combining anti-PD-(L)1 antibodies with hyaluronidase enhances tumor growth inhibition by remodeling the stroma and improving drug delivery in pancreatic cancer models.
• Blocking IL-6 in combination with anti-PD-L1 antibodies inhibits tumor volume and increases survival in preclinical pancreatic cancer models, warranting clinical verification.
• Combining CD40 agonists with PD-L1 blockade improves overall survival and promotes anti-tumor immunity in orthotopic pancreatic cancer mouse models.
• Inhibiting the CXCL12/CXCR4 pathway alongside anti-PD-(L)1 therapy modulates immunosuppression and demonstrates synergistic effects in treating pancreatic cancer.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath